Inspyr Therapeutics, Inc. is a clinical-stage biotechnology company dedicated to developing innovative prodrugs and nanoparticle drug conjugates aimed at improving the safety and efficacy of established chemotherapeutic agents. The company’s proprietary platform leverages a prodrug approach that selectively releases active drug moieties within tumor tissues, potentially reducing systemic toxicity and enhancing anti-tumor activity. Inspyr’s research and development pipeline includes both intravenous and oral formulations of its lead candidates, with early-stage studies focused on solid tumor indications and metastatic disease.
Founded in 2012 as MoyGene and rebranded in 2021 to better reflect its therapeutics focus, Inspyr Therapeutics has built a portfolio designed to address the limitations of existing cancer treatments. Its flagship programs, IV-MITO and oral-MITO, are formulated to deliver a doxorubicin prodrug in a controlled-release manner. Preclinical data suggest these candidates may overcome drug resistance mechanisms and offer a more favorable safety profile compared to standard chemotherapy regimens. Further research is underway to optimize dosing strategies and to support eventual advancement into human clinical trials.
Headquartered in Palo Alto, California, Inspyr Therapeutics operates research facilities in the United States and maintains collaborative relationships with contract development and manufacturing organizations (CDMOs) across North America and Europe. This geographic footprint enables the company to leverage regional expertise in drug formulation, regulatory affairs and clinical trial execution. Inspyr’s strategic partnerships aim to accelerate its pipeline programs through technology transfer and scale-up processes essential for late-stage development and eventual commercialization.
The company’s leadership team brings together seasoned professionals with deep expertise in oncology drug development, regulatory strategy and corporate governance. Under the guidance of its CEO, the board and executive management have pursued a capital-efficient approach to innovation, focusing on value-creation milestones and targeted investor engagement. As Inspyr Therapeutics advances its novel prodrug candidates, it seeks to establish itself as a key player in the next generation of precision oncology treatments.
AI Generated. May Contain Errors.
Free NSPX Stock Alerts